$-0.07
(Market cap
$1,347 Mln
Revenue (TTM)
$38 Mln
P/E Ratio
11.7
P/B Ratio
8.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-5.8 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
149.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$1.7
-
Face value
--
-
Shares outstanding
72,388,316
10 Years Aggregate
CFO
$-596.36 Mln
EBITDA
$-1,013.24 Mln
Net Profit
$-535.52 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Omeros (OMER)
| 10.9 | 51.6 | 87.4 | 355.5 | 75.2 | 3.9 | 5.5 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Omeros (OMER)
| 73.8 | 199.4 | 44.7 | -64.9 | -55.0 | 1.4 | 26.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Omeros (OMER)
|
19.0 | 1,347.2 | 38.4 | 124.8 | 343.8 | -- | 11.7 | 8.4 |
| 17.4 | 6,074.3 | 3,117.6 | 157.4 | 14.7 | -- | 36.3 | 186.5 | |
| 206.5 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 74.2 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 111.2 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.0 | 10,020.9 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 29.3 | 2.5 | |
| 24.4 | 12,236.5 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.9 | |
| 287.5 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 68.4 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 124.7 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Omeros (OMER)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the... Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. Read more
-
Co-Founder, Chairman, CEO & President
Dr. Gregory A. Demopulos M.D.
-
Co-Founder, Chairman, CEO & President
Dr. Gregory A. Demopulos M.D.
-
Headquarters
Seattle, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Omeros (OMER)
What is the current share price of Omeros Corporation (OMER) Today?
The share price of Omeros Corporation (OMER) is $19.04 (NASDAQ) as of 04-Sep-2026 13:37 EDT. Omeros Corporation (OMER) has given a return of 75.21% in the last 3 years.
What is the current PB & PE ratio of Omeros Corporation (OMER)?
The P/E ratio of Omeros Corporation (OMER) is 11.70 times as on 28-Aug-2026, a 69 discount to its peers’ median range of 37.32 times.
The P/B ratio of Omeros Corporation (OMER) is 8.44 times as on 28-Aug-2026, a 9 premium to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-325.61 |
-9.00 |
2024 |
-3.67 |
-3.15 |
2023 |
-1.74 |
-8.23 |
2022 |
2.99 |
1.66 |
2021 |
-3.61 |
16.91 |
What is the 52 Week High and Low of Omeros Corporation (OMER)?
The 52-week high and low of Omeros Corporation (OMER) are Rs 19.65 and Rs 3.94 as of 05-Sep-2026.
What is the market cap of Omeros Corporation (OMER)?
Omeros Corporation (OMER) has a market capitalisation of $ 1,347 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Omeros Corporation (OMER)?
Before investing in Omeros Corporation (OMER), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.